Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 8.37 Million EUR | -22.29% |
| 2022 | 10.77 Million EUR | 2.24% |
| 2021 | 10.53 Million EUR | 0.84% |
| 2020 | 10.45 Million EUR | 32.61% |
| 2019 | 7.88 Million EUR | 42.62% |
| 2018 | 5.52 Million EUR | 13.49% |
| 2017 | 4.86 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 8.61 Million EUR | 2.9% |
| 2024 Q2 | 8.6 Million EUR | -0.19% |
| 2023 Q1 | 11.49 Million EUR | 6.66% |
| 2023 Q3 | 11.39 Million EUR | -0.24% |
| 2023 Q4 | 8.37 Million EUR | -26.53% |
| 2023 Q2 | 11.42 Million EUR | -0.6% |
| 2023 FY | 8.37 Million EUR | -22.29% |
| 2022 Q1 | 10.61 Million EUR | 0.73% |
| 2022 FY | 10.77 Million EUR | 2.24% |
| 2022 Q4 | 10.77 Million EUR | -0.84% |
| 2022 Q3 | 10.86 Million EUR | -0.75% |
| 2022 Q2 | 10.94 Million EUR | 3.13% |
| 2021 Q4 | 10.53 Million EUR | 0.0% |
| 2021 FY | 10.53 Million EUR | 0.84% |
| 2021 Q2 | 10.58 Million EUR | 0.91% |
| 2021 Q1 | 10.49 Million EUR | 0.41% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 10.45 Million EUR | 0.0% |
| 2020 Q3 | 10.45 Million EUR | 27.05% |
| 2020 Q2 | 8.22 Million EUR | 0.0% |
| 2020 FY | 10.45 Million EUR | 32.61% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | 7.88 Million EUR | 0.0% |
| 2019 Q3 | 7.88 Million EUR | 0.0% |
| 2019 FY | 7.88 Million EUR | 42.62% |
| 2018 FY | 5.52 Million EUR | 13.49% |
| 2017 FY | 4.86 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 75.25 Million USD | 88.874% |
| AngioDynamics, Inc. | 3.93 Million USD | -112.567% |
| AtriCure, Inc. | 60.59 Million USD | 86.182% |
| Avinger, Inc. | - USD | -Infinity% |
| Azenta, Inc. | 60.43 Million USD | 86.146% |
| BioLife Solutions, Inc. | 18.31 Million USD | 54.273% |
| The Cooper Companies, Inc. | 2.52 Billion USD | 99.668% |
| Daxor Corporation | 755.65 Thousand USD | -1008.039% |
| Ekso Bionics Holdings, Inc. | 4.83 Million USD | -73.282% |
| Femasys Inc. | 4.25 Million USD | -96.633% |
| GlucoTrack, Inc. | 196 Thousand USD | -4171.938% |
| Harvard Bioscience, Inc. | 30.7 Million USD | 72.73% |
| Hologic, Inc. | 2.49 Billion USD | 99.665% |
| ICU Medical, Inc. | 1.57 Billion USD | 99.469% |
| Intuitive Surgical, Inc. | -82.1 Million USD | 110.199% |
| KORU Medical Systems, Inc. | 3.65 Million USD | -129.214% |
| LeMaitre Vascular, Inc. | 16.62 Million USD | 49.633% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 871.7 Million USD | 99.039% |
| Microbot Medical Inc. | 40 Thousand USD | -20832.498% |
| Meihua International Medical Technologies Co., Ltd. | 4592.00 USD | -182238.828% |
| Merit Medical Systems, Inc. | 823.01 Million USD | 98.983% |
| Nephros, Inc. | 1.39 Million USD | -502.374% |
| NovoCure Limited | 596.24 Million USD | 98.596% |
| NEXGEL, Inc. | 513 Thousand USD | -1532.164% |
| NEXGEL, Inc. | 513 Thousand USD | -1532.164% |
| Singular Genomics Systems, Inc. | 67.52 Million USD | 87.6% |
| OraSure Technologies, Inc. | 11.38 Million USD | 26.475% |
| Pro-Dex, Inc. | 7.53 Million USD | -11.107% |
| Pulse Biosciences, Inc. | 8.08 Million USD | -3.549% |
| Predictive Oncology Inc. | 2.18 Million USD | -282.507% |
| Precision Optics Corporation, Inc. | 1.93 Million USD | -332.05% |
| QuidelOrtho Corporation | 2.27 Billion USD | 99.632% |
| Repligen Corporation | 510.14 Million USD | 98.359% |
| Sanara MedTech Inc. | 9.11 Million USD | 8.122% |
| STAAR Surgical Company | 31.46 Million USD | 73.391% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 295 Thousand USD | -2738.305% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 99.534% |
| Jin Medical International Ltd. | - USD | -Infinity% |